- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Arrivent Biopharma Inc (AVBP)
Arrivent Biopharma Inc stock price live, this page displays NASDAQ AVBP stock exchange data. View the AVBP premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Arrivent Biopharma Inc real time stock price chart below.
What Is the Arrivent Biopharma Inc Stock Price Today?
The Arrivent Biopharma Inc stock price today is 21.63.
What Is the Stock Symbol for Arrivent Biopharma Inc?
The stock symbol for Arrivent Biopharma Inc is "AVBP."
What Stock Exchange Does Arrivent Biopharma Inc Trade On?
Arrivent Biopharma Inc is listed and trades on the NASDAQ stock exchange.
Is Arrivent Biopharma Inc a Good Stock to Buy?
Determining whether Arrivent Biopharma Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AVBP quote. (ISIN: US04272N1028)
What Is the Arrivent Biopharma Inc Stock Price Today?
The Arrivent Biopharma Inc stock price today is 21.63.
What Is the Stock Symbol for Arrivent Biopharma Inc?
The stock symbol for Arrivent Biopharma Inc is "AVBP."
What Stock Exchange Does Arrivent Biopharma Inc Trade On?
Arrivent Biopharma Inc is listed and trades on the NASDAQ stock exchange.
Is Arrivent Biopharma Inc a Good Stock to Buy?
Determining whether Arrivent Biopharma Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AVBP quote. (ISIN: US04272N1028)
NASDAQ
Currency in USD
21.63
-0.40(-1.82%)
Closed·
After Hours
21.69+0.06(+0.28%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
21.39
22.01
52 wk Range
15.47
36.37
AVBP Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
AVBP is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
21.3922.01
52 wk Range
15.4736.37
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AVBP Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
40.22
Upside
+85.96%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell
Arrivent Biopharma Inc Company Profile
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Compare AVBP to Peers and Sector
Metrics to compare | AVBP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAVBPPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.2x | −4.6x | −0.5x | |
PEG Ratio | −0.11 | 0.00 | 0.00 | |
Price/Book | 3.9x | 2.2x | 2.6x | |
Price / LTM Sales | - | 9.6x | 3.2x | |
Upside (Analyst Target) | 84.9% | 154.6% | 45.4% | |
Fair Value Upside | Unlock | 9.4% | 6.9% | Unlock |
Analyst Ratings
9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 40.22
(+85.96% Upside)
Earnings
Latest Release
May 12, 2025
EPS / Forecast
-1.90 / -0.73
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Is the Arrivent Biopharma (AVBP) Stock Price Today?
The Arrivent Biopharma stock price today is 21.63
What Stock Exchange Does Arrivent Biopharma Trade On?
Arrivent Biopharma is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Arrivent Biopharma?
The stock symbol for Arrivent Biopharma is "AVBP."
What Is the Arrivent Biopharma Market Cap?
As of today, Arrivent Biopharma market cap is 790.01M.
What Is Arrivent Biopharma's Earnings Per Share (TTM)?
The Arrivent Biopharma EPS (TTM) is -3.78.
When Is the Next Arrivent Biopharma Earnings Date?
Arrivent Biopharma will release its next earnings report on 12 Aug 2025.
From a Technical Analysis Perspective, Is AVBP a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Arrivent Biopharma Stock Split?
Arrivent Biopharma has split 0 times.
How Many Employees Does Arrivent Biopharma Have?
Arrivent Biopharma has 52 employees.
What is the current trading status of Arrivent Biopharma (AVBP)?
As of 13 July 2025, Arrivent Biopharma (AVBP) is trading at a price of 21.63, with a previous close of 22.03. The stock has fluctuated within a day range of 21.39 to 22.01, while its 52-week range spans from 15.47 to 36.37.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.